Replies to post #22150 on Relief Therapeutics Holding AG (RLFTF)

[chrismisquez]

Being that NeuroRX is getting 50% of the profits from US, Canada, and Israel... RLF100 directly effects their bottom line and the value of the company as a whole. In the event that they wanted to raise any money for other drugs in their pipeline, now would be a good time. If a private equity firm were wanting to get into RLF100, they’d have 2 options. Was Javitt speaking as CEO of NeuroRX, or Executive Vice Chairman of Relief Therapeutics?

Regardless, I’m very bullish, and plan on expanding my position a little more tomorrow. I think the sky is the limit on this company. I was just somewhat expecting an immediate bump from an investor conference. That being said, I know it’s not over and many would like to consider their options before committing. One potential explanation was the private equity opportunity vs the public offering for a stake in the same product.